Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis
In the last decade, anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (SV) has been treated with the anti-B-cell drug, rituximab (RTM) both for induction and maintenance therapy. One of the problems of the treatment with RTM in patients with ANCA-SV is the risk of late-ons...
Zapisane w:
| Główni autorzy: | , , |
|---|---|
| Format: | Artigo |
| Język: | Russo |
| Wydane: |
IMA-PRESS LLC
2022-06-01
|
| Seria: | Современная ревматология |
| Hasła przedmiotowe: | |
| Dostęp online: | https://mrj.ima-press.net/mrj/article/view/1295 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|